-
Mashup Score: 1Why the pharma industry is digging deep in rare disease - 2 year(s) ago
The rare disease market is set for major growth in the decade to come, and pharma companies are securing their footholds now.
Source: PharmaVOICECategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1
As the fallout of the Aduhelm approval continues, scrutiny of the speedier pathway has increased and the pressure is on to close a key gap in the regulation.
Source: PharmaVOICECategories: Latest Headlines, Rare DiseaseTweet-
RT @ABatemanHouse: The spotlight is on accelerated approvals — now FDA could run a tighter ship | PharmaVoice https://t.co/pTmfuEVdjQ
-
-
Mashup Score: 1
As the fallout of the Aduhelm approval continues, scrutiny of the speedier pathway has increased and the pressure is on to close a key gap in the regulation.
Source: PharmaVOICECategories: Latest Headlines, Rare DiseaseTweet-
RT @BrielmaierL: The spotlight is on accelerated approvals — now FDA could run a tighter ship https://t.co/OFMEWl9vAy via @PharmaVoice Br…
-
-
Mashup Score: 1
Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.
Source: PharmaVOICECategories: Latest Headlines, Rare DiseaseTweet-
RT @BrielmaierL: CVS is exiting clinical trials. Does this spell trouble for retail-based research? https://t.co/XdSxD4mUuP via @PharmaVoice
-
-
Mashup Score: 0Reata’s stock plummets amid sudden FDA neuro office shakeup - 2 year(s) ago
The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.
Source: PharmaVOICECategories: Hem/Oncs, Latest HeadlinesTweet-
@pash22 @LogarithmicDis @MemoryDoc @PhilAlz @AlbertoEspay @MadhavThambiset @nvillain_alz @StefanoSensi14 @JosephTherr @VincentPlanche @AE_MD @dmrind @gregggonsalves @ProfRobHoward @LonSchneiderMD @seb_walsh @ayton_scott @reshmagar @jasonkarlawish @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @Kariem_Ezzat @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @DrLiHueiTsai @adamfeuerstein @Jasonmmast @damiangarde @lauriemcginley2 @grace_huckins @aylinsdincer @PamBelluck @schrag_matthew @kathy_y_liu @biogen @EisaiUS @naomikresge @DrMariaALZ @alzassociation @barttels @NeuroAdvisor @MedicareGov @BrettArends @US_FDA You could be correct. Also I could need to calibrate my priors slightly downwards. https://t.co/YnDpeQ3UYS
-
-
Mashup Score: 1Cytokinetics looks to muscle into the cardiovascular market - 2 year(s) ago
With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.
Source: PharmaVOICECategories: Latest Headlines, Rare DiseaseTweet-
RT @BrielmaierL: Cytokinetics looks to muscle into the cardiovascular market https://t.co/WH9hwwVHLm via @PharmaVoice In some ways, our AL…
-
-
Mashup Score: 1Nonprofits are bridging R&D’s valley of death - 2 year(s) ago
How charitable firms such as Advancium are helping to right the market wrongs of drug development.
Source: PharmaVOICECategories: Latest Headlines, Rare DiseaseTweet-
RT @BrielmaierL: Nonprofits are bridging R&D’s valley of death https://t.co/ibV5rczAaA via @PharmaVOICE several groundbreaking new drugs…
-
-
Mashup Score: 010 of our most popular articles in 2022 - 2 year(s) ago
Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.
Source: PharmaVOICECategories: Future of Medicine, Latest HeadlinesTweet-
Our partnership with @CVSHealth is a huge step towards improving clinical trial recruitment & inclusivity! We’re excited that this story was among @PharmaVoice's top stories of 2022. Check it out, and read the other exciting trends that topped the charts: https://t.co/ANlN3Tak9O
-
-
Mashup Score: 5
The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.
Source: PharmaVOICECategories: Future of Medicine, Latest HeadlinesTweet-
RT @EvanKirstel: From vineyards to antivirals, Gilly Regev brings creative thinking to #science https://t.co/21zMryb2pI via @PharmaVOICE…
-
-
Mashup Score: 0
A former agent for The Rolling Stones has launched a healthcare streaming platform with a cast of entertainment heavyweights — and he wants pharma to be a headline act.
Source: PharmaVOICECategories: Healthcare Professionals, Latest HeadlinesTweet-
How a rock 'n' roll guru is putting a new spin on health education for patients | @PharmaVoice https://t.co/gvpsx3XOmi
-
RT @BrielmaierL: Why the pharma industry is digging deep in rare disease https://t.co/yXLZ24pudo via @PharmaVoice the space isn’t without…